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Owing to the involvement of cyclooxygenase-2 (COX-2) in carcinogenesis, COX-2-selective inhibitors are 
increasingly studied for their potential cytotoxic properties. Moreover, the incorporation of carboranes 
in structures of established anti-inflammatory drugs can improve the potency and metabolic stability 
of the inhibitors. Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that 
display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for 
melanoma and colon cancer cell lines over normal cells. furthermore, it was shown that the carborane-
modified derivatives of rofecoxib showed different modes of action that were dependent on the cell type.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used therapeutics for the treatment 
of pain and inflammation1. Their molecular target is the enzyme cyclooxygenase (COX), which catalyzes the 
dioxygenation/cyclization of arachidonic acid to form prostaglandin H2 (PGH2), which is further metabolized 
to prostaglandins (PGs), which in turn act as mediators of inflammation2. The enzyme occurs as two isoforms: a 
constitutive one, namely COX-1, producing a basic level of PGs, and an inducible one, namely COX-2, activated 
by inflammatory stimuli3. COX-2 expression is also upregulated in multiple human cancers4,5. There is a substan-
tial body of evidence that genetic deletion or pharmacological inhibition of COX-2 abrogates tumorigenesis6–11. 
Thus, NSAIDs, in particular COX-2-selective inhibitors, have garnered attention as potential cytostatic drugs. For 
example, rofecoxib was shown to exhibit excellent potential as a cytotoxic agent8,12–15. In addition to inhibition 
of COX, it was demonstrated that the cytotoxic activity of NSAIDs also involves the inhibition of other cellular 
targets.
Unfortunately, the widespread use of COX-2-selective inhibitors revealed an increased risk for cardiovascu-
lar adverse effects in long-term therapy16,17. This prompted research into the development of COX-2-selective 
inhibitors with improved cardiovascular safety profiles. One promising approach is the incorporation of nitric 
oxide (NO)-releasing moieties into the structures of COX inhibitors, given that NO has vasodilatory activity and 
inhibits platelet aggregation18–22. Moreover, as NO plays an important role in the formation and progression of 
various cancers23, NO-releasing analogues of rofecoxib (Fig. 1) were evaluated for their cytotoxic potency. These 
compounds retained an inhibitory potential against COX-2 similar to that of rofecoxib but exhibited even higher 
cytotoxic activity24,25.
The highly dynamic field of drug design and synthesis is constantly in search of new pharmacophores. 
Recently, polyhedral heteroboranes, namely dicarba-closo-dodecaboranes (carboranes)26, have been increasingly 
studied as hydrophobic moieties27,28. Carboranes are icosahedral clusters composed of ten BH and two CH ver-
tices; different positions of the CH vertices give rise to ortho (1,2-), meta (1,7-), and para isomers (1,12-dic- 
arba-closo-dodecaborane)29. On the basis of their hydrophobicity and similarity in dimensions to a phenyl ring 
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(diameter of carborane: 5.25 Å, diameter of a phenyl ring: 4.72 Å), they are regarded as phenyl mimetics27,28. 
Furthermore, carboranes are expected to be resilient to metabolic transformations, and thus may enhance the 
metabolic stability of known drugs28,30. Moreover, one BH vertex can be removed from the icosahedral carborane 
cluster to generate nido-carboranes. These nido clusters complement the functional variety of carboranes and, due 
to their anionic character, can significantly increase the water solubility of the compounds31,32.
It has been shown that the incorporation of a carboranyl moiety in place of a phenyl ring in scaffolds of 
established NSAIDs can lead to compounds with improved activity33–37, not only against COX, but also against 
other targets, such as transthyretin and aldo/keto reductase 1A138,39. Herein, we report the synthesis of five 
carborane-containing derivatives of rofecoxib as well as their COX inhibitory potential and cytotoxic properties.
Results and Discussion
Molecular design and synthesis of rofecoxib analogues. Metabolic transformation of rofecoxib 
occurs at the unsubstituted phenyl ring40, and hence a carborane cluster was introduced instead at the 3-position 
of the butenolide ring of rofecoxib (Fig. 2). o-Carborane was selected because it can easily be transformed into a 
nido cluster. Moreover, it is known that substituents at the para position of the second phenyl ring in rofecoxib 
contribute to the COX-2 selectivity of the inhibitor and its analogues41,42. Therefore, carboranyl analogues with 
different substituents at this position, including a nitrate moiety as in previously reported NO-releasing rofecoxib 
prodrugs, were synthesized (Fig. 1)25.
Preferably, the carborane cluster is inserted last in the proposed structure to minimize potential loss of the 
cluster over multiple synthetic steps. This meant that a bond had to be formed between the cluster and the vinyl 
carbon atom at the 3-position of the butenolide ring. Accordingly, a copper-catalyzed C–C coupling reaction 
with elevated temperatures and long reaction times was performed43,44. However, this approach did not yield the 
desired product, because the butenolide ring proved to be labile under the required basic conditions at elevated 
temperatures45.
Ultimately, an alternative route was followed that involved a ring-closing reaction of esters 3a–c, which 
were obtained by condensation of carboranyl derivative of acetic acid 1 and α-halo-substituted ketones 2a–c 
(Fig. 2). Compound 1 was obtained by treating the sodium salt of o-carborane with sodium iodoacetate in liquid 
ammonia. This reaction provides higher yields with o-carborane than with m- or p-carborane46. However, as 
o-carborane is highly susceptible to deboronation, precautionary measures must be taken when bases are used 
in subsequent steps. Thus, in contrast to a previously reported procedure47, diisopropylethylamine (DIPEA), a 
sterically hindered base that acts as a good proton scavenger but exhibits low nucleophilicity, was used in the 
first step. In the second step, a stronger base, namely NaH, was used because the methylene protons adjacent 
to the carborane cluster are less acidic than those in the previously reported phenyl analogue of 3a–c. With this 
synthetic procedure, esters 3a–c and ultimately three carboranyl derivatives of rofecoxib, 4a–c, were synthesized.
In an attempt to obtain an NO-releasing NSAID, a nitrate derivative 5 was also synthesized (Fig. 3). With 4c 
as starting material, the hydroxyl group was substituted with the better leaving group bromo, which was subse-
quently replaced by the nucleophilic nitrate ion from AgNO3.
Furthermore, a nido derivative of analogue 4b was obtained by a deboronation reaction in wet methanol with 
sodium acetate as base (Fig. 4).
Figure 1. Rofecoxib (left) and NO-releasing rofecoxib analogues (center and right)24,25.
Figure 2. Synthesis of o-carboranyl analogues of rofecoxib 4a–c; (i) Hünigs base (DIPEA), dimethyl sulfoxide 
(DMSO), 2 h, room temperature; (ii) NaH, anhydrous DMSO, 0 °C.
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All five carborane-containing rofecoxib analogues (4a–c, 5, and 6) as well as the ester intermediates 3a–c were 
fully characterized by 1D and 2D NMR spectroscopy, mass spectrometry, elemental analysis, and X-ray crystal-
lography (Fig. 5; SI, Tables S1–S8, Figs. S1–S8).
COX inhibition.  The synthesized compounds were tested in vitro for their potential to inhibit ovine COX-1 
and human recombinant COX-2. This was done by employing a commercial COX assay (COX Fluorescent 
Inhibitor Screening Assay Kit, Item No. 700100, Cayman Chemical, Ann Arbor, MI). Of the five synthesized 
analogues, only nido derivative 6 was found to be a weak COX-2-selective inhibitor (IC50 (COX-2): 69.63 µM, 
IC50 (COX-1) > 100 µM) (Fig. 6; SI, Fig. S9, Table S9), whereas the other analogues did not exhibit any inhibitory 
activity (SI, Table S9, Fig. S10).
To explain the inactivity, which likely resulted from a lack of binding to COX, molecular docking studies were 
performed for the synthesized inhibitors. It was found that all analogues bearing a p-substituted benzene ring (4b, 
4c, 5, and 6) bind in a manner similar to rofecoxib (Fig. 6). The p-substituted benzene ring was inserted in the side 
pocket of the active site of COX-2, while the butenolide ring faced towards the lobby region of the active site of 
the enzyme with the lactone oxygen atom close to Arg120. Furthermore, the carborane cluster was nestled in the 
main pocket of the active site and formed hydrophobic interactions with multiple residues. In contrast, analogue 
4a bearing an unsubstituted benzene ring proved to have a different mode of binding than rofecoxib; the phenyl 
ring pointed towards the main pocket of the active site, while the carborane was oriented towards Leu531 (Fig. 7). 
Figure 3. Synthesis of a nitrate derivative of rofecoxib; (i) AgNO3, PPh3, N-bromosuccinimide (NBS), MeCN, 
2.5 h at 60 °C.
Figure 4. Synthesis of a nido-carboranyl analogue of rofecoxib; (i) NaOAc, CH3OH, 65 °C, 48 h.
Figure 5. Crystal structures of analogues 4b (left) and 5 (right). (ORTEP representation: displacement thermal 
ellipsoids are drawn at 50% probability).
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This observation coincides with previous reports that polar substituents contribute to the COX-2 selectivity of 
rofecoxib and its analogues41,42. Whereas a binding free energy of –6.9 kcal/mol was calculated for rofecoxib, all 
inhibitors, except for 4b, yielded higher binding energies indicating lower binding affinity than rofecoxib. This 
finding is consistent with the fact that the newly synthesized compounds either do not inhibit COX (4a–c and 5) 
or are poor inhibitors (6, exists as two enantiomers, R and S) (Fig. 7).
Antitumor activity. Rofecoxib and its carborane-based analogues were tested against four melanoma (A375, 
518A2, B16, B16F10) and four colon cancer (HCT116, SW480, SW620, CT25CL26) cell lines. Both melanoma and 
colon cancer are tumor types tightly connected with inflammation, while the expression of COX-2 in the selected 
cell lines was highly variable. Since a lot of discrepancies were found in the literature concerning the expression 
of this enzyme5,48–53, both COX-1 and COX-2 expression was analyzed by Western blot. While COX-1 was uni-
formly expressed in all tested cell lines, 518A2 and A375 showed higher expression of COX-2 (SI, Fig. S14) in 
comparison to other tested cell lines. The cells were treated with a wide range of doses of 4a–c, 5, and 6 for 48 h and 
cell viability was determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and CV 
(crystal violet) assays. The obtained IC50 values were similar for both assays (Table 1). Compound 6 was inactive 
against all cell lines with the exception of 518A2; 4a–c showed similar efficacy against all tested cell lines (Fig. S12 
and S13). Compound 5 caused the highest decrease in cell viability in all of the melanoma cell lines, whereas 
growth inhibition of the colon cancer cell lines was similar to those of the other rofecoxib analogues (Table 1).
The COX-2-expressing melanoma cell lines A375 and 518A2 were the most sensitive to 5. However, 5 also 
inhibited the growth of the other tested cell lines, including those with a low level of COX-2 expression. This 
observation in addition to the weak COX-2 inhibition indicates that the antitumor action of this compound may 
be mainly COX-2-independent. Moreover, the treatment of A375 cells with rofecoxib did not result in signif-
icantly decreased viability, and this suggested that the cytotoxicity of the carborane analogues is related to the 
carborane substitution (Fig. 8).
In addition to A375 cells, rofecoxib is known to be inactive against COX-2-overexpressing (HCA-7) and 
COX-2-negative (HCT-116) human colon cancer cell lines54,55. On the other hand, rofecoxib was previously 
shown to inhibit the proliferation of a variety of cancer cell lines, including COX-2-overexpressing and COX-
2-negative cells12,14,15,56,57. These observations indicate that the antitumor action of rofecoxib can be ascribed to 
COX-2-independent effects58. In addition, it can be inferred that the antitumor potential is not a general feature 
of rofecoxib but rather defined by some cellular specificity.
A selectivity index was calculated by dividing the IC50 of the compound’s cytotoxicity determined for mac-
rophages (SI, Table S10) by that determined for the given cell line. In agreement with the observed experimental 
effectiveness of the compounds toward the malignant phenotype, the highest selectivity index was calculated for 
5 (SI, Table S11,). Thus, further investigations were conducted in which A375 and 518A2 cells were exposed to 5.
It is known that the A375 cell line has a heterogeneous morphology with a subpopulation of highly metastatic 
oval cells59. Light microscopy of A375 cultures after incubation with 5 revealed not only a decrease in the number 
of viable cells, but also a more pronounced decrease in oval cells compared to fibroblast-like cells (% of oval vs. 
fibroblast: 46 ± 2.8 vs. 54 ± 3.2 in the control; 28 ± 2.6* vs. 72 ± 7.4* in the treated cells, *p < 0.05 in comparison 
to control) (SI, Fig. S11). Thus, it can be concluded that compound 5 affected the two populations in different 
manners with a stronger effect on the metastatic oval cells. On the other hand, on treatment with 5, 518A2 cells 
showed a pattern typical for pronounced cell death, whereby numerous detached, round cells were observed.
Incubation of the A375 cell line with 5 for 48 h did not promote significant apoptosis, as estimated by Ann/PI 
(AnnexinV-FITC/propidium iodide) double staining (Fig. 9A), and only a slight enhancement of total caspase 
activity was observed by a pan-caspase inhibitor, ApoStat (Fig. 9B). Conversely, 518A2 cells displayed strong 
caspase-dependent apoptosis with an elevated percentage of both early Ann+PI− and late apoptotic Ann+PI+ 
cells (Fig. 9).
While in the 518A2 cell culture apoptosis was evident, even prolonged incubation of A375 cells with 5 for an 
additional 24 h (72 h total) was not accompanied by the appearance of apoptotic cells (not shown). Furthermore, 
the findings of a scratch test performed on both melanoma cell lines treated with 5 showed that 518A2 cells pref-
erentially died while A375 cells revealed inhibited proliferation and migration toward the wound region. It was 
observed that the wound in the control of the A375 cells decreased from 172 ± 69 μm to 127 ± 13 μm, compared 
to the treated cells where it stayed at 177 ± 32 μm. In the 518A2 scratch test the wound in the control almost 
closed (54 ± 12 μm in comparison to 154 ± 2 μm at time 0, p < 0.05), whilst it was impossible to distinguish 
Figure 6. Inhibition of COX-2 by the rofecoxib analogues 4a–c, 5, and 6. Error bars indicate standard error 
mean (SEM) obtained from two measurements at each concentration.
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the edges of the wound in the cells exposed to compound 5 due to the presence of numerous floating dying 
cells. (Fig. 10A).To confirm this, the cell proliferation rate was determined after 72 h of incubation in the pres-
ence of 5 of the carboxyfluorescein succinimidyl ester (CFSE)-stained cells. The obtained data revealed a strong 
inhibition of A375 cell division manifested through accumulated undivided cells in comparison to a control of 
untreated cells (% of undivided cells in treated cultures was elevated for 38 ± 8, p < 0.05 in comparison to control) 
(Fig. 10B). These findings were further confirmed by fluorescence microscopy of 4′,6-diamidino-2-phenylindole 
(DAPI)-stained cells (Fig. 10C), for which predominantly large nuclei with scarce nucleoli characteristic for inter-
phase were observed on treatment of A375 cells with 560. In addition, sporadic oblong nuclei with condensed 
chromatin, typical for apoptosis, were also observed (25 ± 9%). On the other hand in the DAPI-stained 518A2 
cells typical apoptotic shrunken nuclei and apoptotic bodies were dominant (60 ± 2%)61. The different modes of 
Figure 7. Docked conformations of the carboranyl rofecoxib analogues 4a–c, 5 and 6. In parentheses, 
calculated free energies of binding are given in kcal/mol. Magenta wireframe: superimposed experimental 
binding pose of rofecoxib from PDB ID: 5KIR. Hydrogen bonds are shown as magenta solid lines. Hydrogen 
atoms are not shown for clarity.
IC50 (µM)
Compound 4a 4b 4c 5 6
Test MTT CV MTT CV MTT CV MTT CV MTT CV
Cell line*
A375 20.15 ± 1.26 15.95 ± 1.65 16.85 ± 1.35 14.05 ± 0.75 17.95 ± 1.26 10.5 ± 0.75 4.25 ± 1.65 4.7 ± 0.30 >50 >50
518A2 18.95 ± 1.63 21.4 ± 0.42 13.75 ± 0.21 14.75 ± 0.92 36.35 ± 0.21 41.2 ± 2.12 5.15 ± 0.64 5.5 ± 0.57 36.85 ± 0.49 49.7 ± 0.42
B16 30.8 ± 2.81 30.55 ± 3.86 18 ± 1.71 22.15 ± 0.65 26.05 ± 2.49 30.8 ± 3.22 10.1 ± 0.40 11.45 ± 1.05 >50 >50
B16F10 24.3 ± 2.01 25.4 ± 2.41 27.3 ± 2.82 26.6 ± 2.62 28 ± 2.62 26.5 ± 2.62 7.95 ± 3.06 7.65 ± 0.26 >50 >50
HCT116 13.5 ± 0 12.8 ± 0.5 42.5 ± 1.42 35.9 ± 0 22.15 ± 0.95 19.25 ± 1.46 8.9 ± 0 9.95 ± 0.95 >50 >50
CT26CL25 42.65 ± 3.17 37.2 ± 2.21 38.1 ± 0.9 36.05 ± 1.25 28.45 ± 2.46 29.25 ± 2.86 31.45 ± 3.27 29.4 ± 2.12 >50 >50
SW480 22.8 ± 0.7 19 ± 1.91 42.5 ± 0 35.9 ± 0 24.15 ± 1.05 26.8 ± 2.81 16.6 ± 1.01 8.6 ± 0.21 >50 >50
SW620 24.7 ± 0.42 24.75 ± 0.35 19.25 ± 0.78 21.75 ± 0.64 35.7 ± 0.85 44.35 ± 1.77 10.5 ± 0.14 10.75 ± 0.21 >50 >50
Table 1. IC50 values for compounds 4a–c, 5, and 6 for the growth inhibition of different melanoma and colon 
cancer cell lines, obtained from MTT and CV assays (three independent experiments each). *A375, human 
melanoma; 518A2, human melanoma; HCT116, human colon carcinoma; SW480, human colon carcinoma; 
SW620, human colon carcinoma; B16, mouse solid melanoma; B16F10, mouse metastatic melanoma; 
CT25CL26, mouse colon carcinoma.
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action on the two melanoma cell lines indicate that cell specific characteristics define the outcome of the treat-
ment with 5. In comparison, previous studies showed that rofecoxib inhibited proliferation and induced apop-
tosis as the main mechanism of cell death12,14,15,57. Recent data on the compensatory proliferation in response to 
induced apoptotic cell death in the tumor tissue even favor a nonaggressive approach in the therapy of advanced 
malignancy62.
Given that analogue 5 is designed for NO release, the intracellular release of nitric oxide and production of 
reactive oxygen species (ROS)/reactive nitrogen species (RNS) was measured by means of redox-sensitive dyes — 
4-amino-5-methylamino-2′,7′-difluorofluorescein diacetate (DAF) and dihydrorhodamine-123 (DHR) — after 
exposure for 48 h (Fig. 11). While a moderate increase of NO was observed in both cell lines (mean fluorescence: 
40 ± 7 vs. 60.5 ± 9.1* in A375 cells, and 44.9 ± 5.9 vs. 97.7 ± 1.2* in 518A2 cells, *p < 0.05 refers to untreated 
cultures), a slight increase in ROS/RNS production was detected only in A375 cultures treated with 5 (mean 
fluorescence: 22.3 ± 5 vs. 32.67 ± 8* in A375 cells, and 70.7 ± 5.5 vs. 65.6 ± 0.9 in 518A2 cells, *p < 0.05 refers 
to untreated cultures). It is well documented that highly intensified production of ROS/RNS is connected with 
extreme cell damage and consequent cell death, whereas moderate ROS production is involved in the regulation 
of intracellular processes often involved in cell cycle arrest, proliferation, and differentiation63,64. Apart from the 
moderate intracellular NO release, it was important to evaluate whether 5 released NO extracellularly. The pro-
duction of NO from a nitrate group is a three-electron reduction process that can happen by a number of possible 
Figure 8. Effect of rofecoxib and analogue 5 on the viability of cancer cells. Melanoma (A) and colon cancer 
cells (B) were exposed to 5 or rofecoxib (C, only A375 cells) for 48 h and the number of viable cells was analyzed 
by MTT (left panel) or CV (right panel) assay method. The data are presented as percentage of control ± SD 
from one representative out of three independent experiments.
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2e– and 1e– pathways, commonly involving the initial liberation of a nitrite65. A common method of detecting 
the release of NO in the extracellular compartment is the detection of nitrite ions by the Griess reaction, which 
quantifies the nitrite resulting from the oxidation of NO66,67. By this method, no spontaneous NO release from 
5 upon incubation in the culture medium or the conditioned culture medium (conditioned culture medium is 
enriched with soluble cellular products or cell membrane fragments) was detected. Additionally, the NO release 
was measured in the supernatants of A375 cells exposed to 5 for 48 h, and again no spontaneous NO release 
was observed in the extracellular compartment. It can be concluded that 5 did not release NO spontaneously in 
the culture medium or in the extracellular compartment above the detection threshold for the Griess reaction 
method (approximately 2 μM). Although the introduction of the nitrate moiety resulted in enhanced antitumor 
potential of 5 compared to the other carboranyl analogues of rofecoxib, this is probably not solely a consequence 
of NO release. Introduction of a nitrate moiety was also found to be beneficial in the case of rofecoxib. Bocca et 
al. showed that a dinitrate-modified rofecoxib analogue (Fig. 1) had a stronger antiproliferative activity against 
COX-2-positive HT-29 human colon cancer cells than COX-2-negative SW-480 human colon cancer cells25. They 
demonstrated that, even though COX-2 was inhibited with similar potency, the antitumor potential of the inhib-
itor was amplified as a consequence of the nitrate modification. Given that analogue 5 also bears a nitrate group 
and did not inhibit COX-2, further investigations will be needed to better understand the mechanism of action 
for the observed cytostatic activity.
conclusion
We have reported the synthesis of five carborane-containing derivatives (4a–c, 5, and 6) of rofecoxib in which 
the phenyl ring in the 3-position in the original structure of rofecoxib was substituted with an o-carborane or a 
nido-carborane cluster. All compounds were tested for their COX-inhibitory and cytotoxic activity. Compounds 
4a–c and 5 proved to be inactive against COX, whereas nido analogue 6 exhibited weak COX-2 inhibition. Despite 
that, compounds 4a–c and 5 exhibited cytotoxic activity against colon cancer and melanoma cell lines. The mode 
of action of 5 was exemplarily studied on two melanoma cell lines, i.e., A375 and 518A2. While the prolifera-
tion and invasiveness of the A375 cell line was greatly inhibited, for the 518A2 cell line caspase-dependent cell 
Figure 9. Effect of 5 on apoptosis and caspase activation of A375 and 518A2 cells. Cells were exposed to 5 for 
48 h, and apoptosis (A) and caspase activation (B) were assessed by flow cytometry. The data are presented as a 
representative dot plot or histogram (left panel) and mean ± SD obtained from three independent experiments 
(right panel). *p < 0.05 refers to untreated cultures.
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death was promoted. These studies provide a foundation for further investigations into analogues of established 
NSAIDs with improved cytotoxic activities.
experimental part. Materials and methods. All commercial reagents and solvents were used without fur-
ther purification. Reactions involving carboranes were carried out under nitrogen atmosphere by using standard 
Schlenk techniques. Compounds 2a–c were prepared by a previously reported method68. For column chromatog-
raphy, silica gel 60 Å from ACROS was used. The particle size was in the range of 0.035 to 0.070 mm. To monitor 
the reaction progress of the syntheses, thin layer chromatography was used. For this purpose, glass plates coated 
with silica gel 60 F254 from MERCK were used. Carborane-containing areas were stained with a 5% solution of 
palladium(II) chloride in methanol. All 1H, 13C, and 11B NMR spectra were measured with an ADVANCE DRX 
400 spectrometer from BRUKER. The chemical shifts are reported in parts per million (ppm). Quaternary carbon 
atoms were not always observed because of their long relaxation times. The melting points were determined in 
glass capillaries with a GALLENKAMP apparatus and are uncorrected. IR spectra were obtained using a FTIR 
spectrometer (GENESIS ATI, Mattson/Unicam) in the range of 400–4000 cm−1 in KBr. The positive or negative 
mass spectra were recorded with a BRUKER Daltonics APEX II FT-ICR spectrometer. For these measurements, 
dichloromethane, acetonitrile, methanol, or a mixture of these solvents was used.
Carboranyl acetic acid (1). 10 g (69.44 mmol) o-carborane, dissolved in 30 mL dry ethyl ether, was added to 
a stirred solution of 2.7 g (69.23 mmol) sodium amide in 150 mL dry liquid ammonia. The reaction mixture 
was left to stir at −50 °C under a nitrogen atmosphere. After 1 h of stirring, 14.4 g (69.23 mmol) neat sodium 
Figure 10. Effect of 5 on the cell proliferation of A375 and 518A2 cells. Cells were exposed to 5, and cell 
migration after 48 h was analyzed by light microscopy. (A) A375 cell proliferation after 72 h was assessed by 
flow cytometry. (B) Treatments with 5 are presented as black-lined histograms, and controls as gray histograms; 
the represented histogram was selected out of three repeated experiments. Fluorescence microscopy of DAPI-
stained A375 and 518A2 cells after 72 h incubation with 5, magnification 400× (C).
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iodoacetate was added. The ammonia was allowed to slowly evaporate from the reaction mixture, leaving the 
ethereal fraction. 30 mL of n-hexane and 30 mL of water were added to the resulting slurry. The organic layer 
was separated and the aqueous phase was acidified with concentrated HCl. The precipitated carboranyl acetic 
acid was extracted with diethyl ether. After removal of the organic solvent the crude carboranyl acetic acid was 
purified by recrystallization from n-heptane/toluene (1:1) as colorless needles. The yield of the pure product was 
60% (8.41 g, 41.66 mmol). 1H NMR (CDCl3, 400 MHz): δ = 4.83 (s, 1 H, CHcluster), 3.33 (s, 2 H, CH2), 3.06–1.45 
(m, 10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −2.0 (s, 1B), −4.8 (s, 1B), −9.1 (s, 2B), −10.5 (s, 2B), 
−12.0 (s, 2B), −12.7 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 170.8 (COOH), 67.1 (qCcluster), 58.6 (CHcluster), 
40.9 (CH2).
2-Phenyl-2-oxoethyl 2-(1,2-dicarba-closo-dodecaboranyl)acetate (3a). 1 g (4.94 mmol) carboranyl acetic acid and 
1.37 g (6.88 mmol) of 2a were dissolved in 50 mL DMSO. 0.4 mL DIPEA were added at room temperature to the 
stirred reaction mixture. The reaction was monitored by TLC (n-hexane/ethyl acetate, 2:1). After the starting 
material was consumed, 50 mL of a 2 M HCl were added with ice cooling. The resulting precipitate was extracted 
with two 50 mL portions of ethyl acetate. The organic layer was washed with 50 mL water and brine and then 
dried with MgSO4, and the solvent was removed under reduced pressure. The crude product was purified by 
column chromatography (n-hexane/ethyl acetate, 2:1) to afford a pale yellow solid. The yield of the pure product 
was 80% (1.26 g, 3.95 mmol); mp: 97–98 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.90 (d, 3JHH = 8 Hz, 2 H, CHaromat), 
7.65 (d, 3JHH = 8 Hz, 1 H, CHaromat), 7.51 (t, 3JHH = 8 Hz, 2 H, CHaromat), 5.39 (s, 2 H, CH2), 4.71 (s, 1 H, CHcluster), 
3.46 (s, 2 H, CH2), 2.99–1.46 (m, 10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −2.3 (s, 2B, BH), −5.0 (s, 
1B), −9.0 (s, 2B), −10.3 (s, 2B), −12.2 (s, 1B), −12.8 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 190.9 (CO), 
166.5 (COO), 134.4 (qCaromat), 133.4 (qCaromat), 129.0 (CHaromat), 127.8 (CHaromat), 67.6 (qCcluster), 66.9 (COCH2O), 
59.2 (CHcluster), 41.4 (CH2COO); IR (KBr): v 3090= (m; ν(C-Haromat)), 2566 (m; ν(B-H)), 1760 (s; ν(C = O)), 1337 
(m; ν(C-O)), 1178 cm−1 (m; ν(C-O)); HR-ESI-MS (positive mode, ACN) m/z [M + Na]+: Calcd. for 
C12H20B10O3Na: 344.2277, found: 344.2218. Elemental analysis: Calcd. for C: 44.99, H: 6.29; Found for C: 45.29, 
H: 6.23.
2-[4-(Methylsulfonyl)phenyl]-2-oxoethyl 2-(1,2-dicarba-closo-dodecaboranyl)acetate (3b). Starting from 1 g 
(4.9 mmol) of 1, the ester 3b was obtained in a procedure similar to that of ester 3a. Purification was carried out 
by column chromatography (n-hexane/ethyl acetate, 4:1). The pure product was obtained as a pale yellow solid in 
80% yield (1.56 g, 3.92 mmol); mp: 101–102 °C. 1H NMR (CDCl3, 400 MHz): δ = 8.10 (m, 4 H, CHaromat), 5.40 (s, 
2 H, CH2), 4.59 (s, 1 H, CHcluster), 3.47 (s, 2 H, CH2), 3.10 (s, 3 H, CH3), 3.05–1.6 (m, 10 H, BHcluster); 11B{1H NMR 
(CDCl3, 128 MHz): δ = −2.1 (s, 2B), −4.9 (s, 1B), −9.0 (s, 2B), −10.4 (s, 2B), −12.1 (s, 1B), −12.7 (s, 2B); 13C{1H} 
NMR (CDCl3, 125 MHz): δ = 190.0 (CO), 166.5 (COO), 145.4 (qCaromat), 137.4 (qCaromat), 128.7 (CHaromat), 128.2 
(CHaromat), 66.8 (COCH2O), 59.1 (CHcluster), 44.3 (CH3SO2), 41.3 (CH2COO); IR (KBr):  =v 3220(m; 
ν(C-Haromat)), 2570 (m; ν(B-H)), 1750 (s; ν(C = O)), 1705 (s; ν(C = O)), 1315 (m; ν(S = O)), 1185 cm−1 (m; 
Figure 11. Effect of 5 on intracellular NO and ROS/RNS production in A375 (upper panel) and 518A2 
(lower panel) cells. Intracellular NO (A) and ROS/RNS (B) were measured after 48 h incubation with 5 by 
flow cytometry. Treatments with 5 are presented as black-lined histograms, controls as gray histograms; the 
represented histogram was selected out of three repeated experiments.
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ν(S = O)); HR-ESI-MS (negative mode, CH3CN) m/z [M-H]−: calcd. for C13H21B10O5S: 397.2119, found: 
397.2130; m/z [M-H2O-H]−: calcd. for C13H19B10O4S 379.2007, found: 379.2021. Elemental analysis: Calcd. for C: 
39.19, H: 5.57, S: 8.05; Found for C: 38.95, H: 5.63, S: 8.21.
2-[4-(Hydroxymethyl)phenyl]-2-oxoethyl 2-(1,2-dicarba-closo-dodecaboranyl)acetate (3c). Starting from 1 g 
(4.9 mmol) of 1, ester 3c was obtained in a procedure similar to that of ester 3a. Purification was carried out by 
column chromatography (n-hexane/ethyl acetate, 2:1). The pure product was obtained as a pale yellow solid in 
54% yield (0.92 g, 2.62 mmol); mp = 95–96 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.89 (d, 3JHH = 8 Hz, 2 H, CHaromat), 
7.51 (d, 3JHH = 8 Hz, 2 H, CHaromat), 5.38 (s, 2 H, CH2), 4.81 (s, 2 H, CH2), 4.71 (s, 1 H, CHcluster), 3.46 (s, 2 H, CH2), 
2.91–1.46 (m, 10 H, BHcluster); 11B NMR{1H} (CDCl3, 128 MHz): δ = −2.3 (s, 2B), −5.0 (s, 1B), −9.0 (s, 2B), −10.3 
(s, 2B), −12.1 (s, 1B), −12.7 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 190.5 (CO), 166.5 (COO), 147.6 (qCaro-
mat), 132.7 (qCaromat), 128.1 (CHaromat), 126.9 (CHaromat), 67.6 (qCcluster), 66.9 (COCH2O), 64.4 (CH2OH), 59.2 
(CHcluster), 41.4 (CH2COO); IR (KBr): v  = 3544 (s; ν(O-H)), 3068 (m; ν(C-Haromat)), 2585 (m; ν(B-H)), 1736 (s; 
ν(C = O)), 1693 cm−1 (s; ν(C = O)); HR-ESI-MS (negative mode, ACN) m/z [M-H]−: Calcd. for C13H21B10O4: 
349.2443, found: 349.2441; (positive mode, ACN) m/z [M + Na]+: Calcd. for C13H22B10O4Na: 373.2419, found: 
373.2389; Elemental analysis: Calcd. for C: 44.56, H: 6.33; Found for C: 44.27, H: 6.33.
4-phenyl-3-(1,2-dicarba-closo-dodecaboranyl)furan-2(5 H)-one (4a). 3a (1 g, 3.12 mmol) was added to a stirred 
suspension of NaH (60% in mineral oil, 124 mg, 3.12 mmol) in 50 mL of dry DMSO. The reaction mixture was left 
to stir for 4 h at room temperature under an atmosphere of nitrogen. After completion of the reaction 50 mL of 
2 M HCl was added with ice cooling. The precipitate was extracted with 2 × 50 mL ethyl acetate. The organic phase 
was washed with 50 mL water and brine after which it was dried with anhydrous MgSO4, and the organic solvent 
was removed under reduced pressure. The crude product was purified with column chromatography (n-hexane/
ethyl acetate, 3:1) that afforded a colorless solid. The yield of the pure product was 74% yield. (0.69 g, 2.3 mmol); 
mp = 88–89 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.50 (m, 3 H, CHaromat), 7.23 (m, 2 H, CHaromat), 5.54 (s, 1 H, 
CHcluster), 4.83 (s, 2 H, CH2butenolide), 2.91–1.34 (m, 10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −2.0 (s, 
2B), −3.0 (s, 1B), −8.9 (s, 2B), −10.7 (s, 1B), −11.9 (s, 2B), −13.3 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): 
δ = 130.2 (CHaromat), 128.8 (CHaromat), 127.2 (CHaromat), 73.2 (CH2 butenolide), 58.0 (CHcluster); IR (KBr): v  = 3090 (m; 
ν(C-Haromat)), 2566 (m; ν(B-H)), 1760 cm−1 (s; ν(C = O)); HR-ESI-MS (negative mode, ACN) m/z [M-H]−: Calcd. 
for C12H17B10O2: 302.2195, found: 309.2194; (positive mode, ACN) m/z [M + Na]+: Calcd. for C12H18B10O2Na: 
325.2207, found: 325.2189. Elemental analysis: Calcd. for C: 47.67, H: 6.00; Found for C: 47.35, H: 5.95.
4-[4-(methylsulfonyl)phenyl]-3-(1,2-dicarba-closo-dodecaboranyl)furan-2(5H)-one (4b). Starting from 1 g 
(2.5 mmol) of 3b, compound 4b was obtained in a procedure similar to that for compound 4a. Purification was 
carried out by column chromatography (n-hexane/ethyl acetate, 3:1). The pure product was obtained as a color-
less solid in 48% yield (0.45 g, 1.2 mmol); mp = 82–83 °C. 1H NMR (CDCl3, 400 MHz): δ = 8.09 (d, 3JHH = 8 Hz, 
2 H, CHaromat), 7.49 (d, 3JHH = 8 Hz, 2 H, CHaromat), 5.60 (s, 1 H, CHcluster), 4.85 (s, 2 H, CH2butenolide), 3.14 (s, 3 H, 
CH3), 2.05–1.14 (m, 10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −2.4 (d, 3B), −8.7 (s, 2B), −11.9 (t, 
5B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 163.7 (qCaromat), 128.6 (CHaromat), 127.9 (CHaromat), 77.9 (CH2butenolide), 
57.9 (CHcluster), 44.4 (CH3SO2); IR (KBr): v  = 3091 (m; ν(C-Haromat)), 2569 (m; ν(B-H)), 1739 (s; ν(C = O)), 1304 
(s; ν(S = O)), 1150 cm−1 (s; ν(S = O)); HR-ESI-MS (negative mode, ACN) m/z [M-H]−: Calcd. for C13H19B10O4S: 
379.2007, found: 379.2021; (positive mode, ACN) m/z [M + Na]+: Calcd. for C13H20B10O4SNa: 409.1983, found: 
409.1959; Elemental analysis: Calcd for C: 41.04, H: 5.30; Found for C: 41.44, H: 5.27.
4-[4-(hydroxymethyl)phenyl]-3-(1,2-dicarba-closo-dodecaboranyl)furan-2(5H)-one (4c). Starting from 1 g 
(2.7 mmol) of 3c, compound 4c was obtained in a procedure similar to that for compound 4a. Purification was 
carried out by column chromatography (n-hexane/ethyl acetate, 3:1). The pure product was obtained as a pale 
yellow solid in 33% yield (0.31 g, 0. 9 mmol); mp: 103–104 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.50 (d, 
3JHH = 7.5 Hz, 2 H, CHaromat), 7.24 (d, 3JHH = 7.5 Hz, 2 H, CHaromat), 5.54 (s, 1 H, CHcluster), 4.82 (s, 2 H, CH2butenolide), 
4.80 (s, 2 H, CH2), 1.80 (s, 1 H, OH), 2.86–1.30 (m, 10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −2.1 (s, 
2B), −3.0 (s, 1B), −8.9 (s, 2B), −10.7 (s, 1B), −11.9 (s, 2B), −13.3 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): 
δ = 170.1 (qCbutenolide), 166.5 (qCaromat), 143.2 (qCaromat), 127.4 (CHaromat), 126.9 (CHaromat), 73.2 (CH2butenolide), 64.5 
(CH2OH), 58.0 (CHcluster); IR (KBr): v  = 3580 (s; ν(O-H)), 3092 (m; ν(C-Haromat)), 2559 (m; ν(B-H)), 1756 cm−1 
(s; ν(C = O)); HR-ESI-MS (negative mode, ACN) m/z [M-H]−: Calcd. for C13H19B10O3: 331.2337, found: 
331.2351; (positive mode, ACN) m/z [M + Na]+: Calcd. for C13H20B10O3Na: 355.2313, found: 355.2289; Elemental 
analysis: Calcd. for C: 46.97, H: 6.06; Found for C: 47.33, H: 5.95.
Synthesis of 4-[4-(methylnitrooxy)phenyl]-3-(1,2-dicarba-closo-dodecaboranyl)furan-2(5 H)-one (5). AgNO3 
(0.306 g, 0.0018 mmol) and Ph3P (0.284 g, 1.1 mmol) were added to a solution of 4c (0.3 g, 0.09 mmol) in dry 
MeCN (20 mL). The mixture was cooled to 5 °C, and N-bromosuccinimide (NBS) (0.192 g, 0.0011 mol) was added 
in portions. Stirring was continued for 1 h at room temperature and then for 2.5 h at 60 °C. Ethyl acetate (30 mL) 
was added to the mixture, and the precipitate was removed by filtration. The filtrate was washed with 50 mL water 
and brine, dried with anhydrous MgSO4, and concentrated under reduced pressure to give a solid, which was 
purified by crystallization from diethyl ether/n-hexane (1:1) to give 5. The yield of the pure product was in 43% 
(0.14 g, 0.03 mmol); mp: 99–100 °C. 1H NMR (CDCl3, 400 MHz): δ = 7.54 (d, 3JHH = 7.5 Hz, 2 H, CHaromat), 7.31 (d, 
3JHH = 7.5 Hz, 2 H, CHaromat), 5.58 (s, 1 H, CHcluster), 5.51 (s, 2 H, CH2), 4.84 (s, 2 H, CH2, butenolide), 2.94–1.39 (m, 
10 H, BHcluster); 11B{1H} NMR (CDCl3, 128 MHz): δ = −1.9 (s, 2B), −3.1 (s, 1B), −8.8 (s, 2B), −10.8 (s, 1B), −11.9 
(s, 2B), −13.2 (s, 2B); 13C{1H} NMR (CDCl3, 100 MHz): δ = 169.8 (CO), 166.5 (qCaromat), 134.6 (qCaromat), 130.8 
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(qCbutenolide), 129.1 (CHaromat), 127.8 (CHaromat), 120.6 (qCbutenolide), 73.6 (CH2ONO2), 73.1 (CH2butenolide), 66.7 
(qCcluster), 57.9 (CHcluster); IR (KBr): v  = 3095 (m; ν(C-Haromat)), 2600 (m; ν(B-H)), 1751 (s; ν(C = O)), 1641 (s; 
ν(N-O)), 1281 cm−1 (s; ν(N-O)); HR-ESI-MS (negative mode, ACN) m/z [M-H]−: Calcd. for C13H18B10NO5: 
376.2188, found: 376.2179; Elemental analysis: Calcd. for C: 41.37, H: 5.07, N: 3.71; Found for C: 41.11, H: 5.07, 
N: 3.56.
Synthesis of R,S-7-(2-oxo-4-(4-sulfamoylphenyl)-2,5-dihydrofuran-3-yl)-7,8-dicarba-nido-dodeca-hydroundecabor
ate(–1) sodium (6). 0.5 g (1.31 mmol) 4b were dissolved in 50 mL methanol and a catalytic amount of sodium 
acetate was added. The reaction mixture was heated to reflux for 48 h, after which Amberlite IR120 (Na+ form) 
was added. After 1 h of stirring at room temperature the solvent was removed under reduced pressure. This 
afforded a viscous oil, which was then purified by column chromatography on silica (n-hexane/ethyl acetate, 1:1; 
then n-hexane/acetone, 1:1). The obtained yellow oil was re-suspended in methanol and the product was precip-
itated with CH2Cl2 as a yellow solid. The yield of the pure product was 98% (0.51 g, 1.29 mmol); mp: 106–107 °C. 
1H NMR (Acetone[D6], 400 MHz): δ = 8.07 (d, 3JHH = 8 Hz, 2 H, CHaromat), 7.88 (d, 3JHH = 8 Hz, 2 H, CHaromat), 4.95 
(dd, 1JHH = 4.65 Hz, 2 H, CH2), 3.19 (s, 3 H, CH3), 1.5 (s, 1 H, CHcluster), 2.58-0.54 (m, 9 H, BHcluster) −2.83 (brs, 1 H, 
endo-H). 11B{1H} NMR (Acetone[D6], ppm): δ = −7.8 (s, 1B), −11.0 (s, 1B), −14.8 (s, 1B), −15.4 (s, 1B), −17.2 
(s, 1B), −20.8 (s, 1B), −21.6 (s, 1B), −32.0 (s, 1B), −35,2 (s, 1B); 13C{1H} NMR (Acetone[D6], 100 MHz): δ = 170.8 
(CO), 154.7 (qCbutenolide), 141.6 (qCaromat), 138.1 (qCaromat), 129.2 (CHaromat), 127.1 (CHaromat), 69.1 (CH2butenolide) 
43.4; IR (KBr): v = 2518 (m; ν(B-H)), 1742 (s; ν(C = O)), 1299 (s; ν(S = O)), 1159 cm−1 (s; ν(S = O)); HR-ESI-MS 
(positive mode, ACN) m/z [M + Na]+: Calcd. for C13H20B9O4SNa2: 416.1751, found: 416.1756. Elemental analysis: 
Calcd. for C: 39.77, H: 5.13, S: 8.17; Found for C: 39.42, H: 5.28, S: 7.91.
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